Immunotherapy

A growing body of research on cancer and cannabis is a testament to the plant’s many uses. Now, a psychologist at the University at Buffalo is studying the effects of cannabis use in oncology patients who receive immunotherapy, a treatment that helps your immune system fight cancer, resulting...

Two big pharma titans are battling for supremacy in the field of oncology immunotherapy. From the looks of it, Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK) may have the upper hand over Bristol-Myers Squibb Co (NYSE: BMY). Before poring over the specifics, here's what...

Bluebird bio Inc (NASDAQ: BLUE) shares were moving to the upside Monday after the announcement of a collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) in a bid to develop cell therapies for cancer. At last check, bluebird bio shares were rallying 2.7 percent to $...

The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was all about competition in the CART-T space. Immunotherapy — the fifth pillar of...

Rodman & Renshaw initiated coverage on OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and $6.00 price target, describing the company as representing a unique opportunity in the oncology sector, positioned in the highly visible and widely-followed immunotherapy domain. Related Link:...

Kite Pharma Inc (NASDAQ: KITE) recently announced that it will be partnering with bluebird bio Inc (NASDAQ: BLUE) to develop second-generation, T-cell receptor product candidates. Arie Belldegrun, Kite Pharma CEO, was recently on CNBC to shed some light on T-cell therapy the company is...